RedHill said it plans to submit an MAA for RHB-101 to treat hypertension under the EU's Mutual Recognition Procedure, with Denmark acting as the reference member state. RedHill said it is "continuing to explore the...

Researchers at The Scripps Research Institute have used a cell-based model of HCV infection to identify compounds on the market or in development for other indications that could be repurposed to treat HCV. 1 But...

Flamel will receive a $4 million milestone from GlaxoSmithKline under a 2004 deal for Flamel to manufacture the pharma's Coreg CR , a controlled-release formulation of the beta blocker Coreg carvedilol to treat heart failure....

GSK terminated development of a fixed-dose combination of Coreg CR and an undisclosed angiotensin-converting enzyme (ACE) inhibitor, which was in Phase III testing to treat hypertension. Coreg CR, which uses Micropump technology from Flamel, is...

Novartis (NYSE:NVS; SWX:NOVN) caused some stir last week when it unveiled plans for a $5 billion bond issue that the company said will be used "for general corporate purposes outside of Switzerland." With Pfizer (NYSE:PFE)...

GlaxoSmithKline (LSE:GSK; NYSE:GSK) said in its 4Q08 earnings that it will expand the restructuring program that the company began in 2007. GSK said it will cut its U.S. primary care sales force by 1,800 and...

FDA last week accepted for filing an NDA for Arca biopharma Inc. 's beta blocker, Gencaro bucindolol. But the company has an interesting circle to square. It is hoping the agency approves bucindolol to treat...